A randomized controlled study of daily aspirin to reduce fibrosis progression in metabolic dysfunction-associated steatotic liver disease

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230705001

Enrollment

108

Registered

2023-07-05

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibrosis progression in metabolic dysfunction-associated steatosis liver disease Aspirin, Fibrosis progression, Metabolic dysfunction-associated steatosis liver disease

Interventions

Aspirin(81) 1 tab oral pc OD x 6 months,Placebo 1 tab oral pc OD x 6 months

Experimental Drug,Placebo Comparator Drug

Aspirin,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with diagnosis of non-alcoholic fatty liver disease 2.No history of aspirin used before

Exclusion criteria

Exclusion criteria: 1.Hepatitis from other causes(viral hepatitis infection, autoimmune) 2.Excess alcohol drinking(140 gram/week in male, 70 gram/week in female) in 2 years before 3.Decompensated cirrhosis 4.Receive other medications(Tamoxifen, Methotrexate, Amiodarone, Valproic acid, Glucocorticoid) in 6 months before 5.Aspirin allergy 6.Pregnancy or breastfeeding 7.History of upper gastrointestinal hemorrhage

Design outcomes

Primary

Measure	Time frame
Liver fibrosis at 3 and 6 months after end of the intervention Vibration controlled transient elastography (Fibroscan)	—

Secondary

Measure	Time frame
Change of score at 3 and 6 months after end of the intervention NAFLD fibrosis score, FIB-4 score, APRI index,Change of alanine transaminase level (ALT) level at 3 and 6 months after end of the intervention alanine transaminase level (ALT) level	—

Countries

Thailand

Contacts

Public ContactKhanisorn Meesri

Phramongkutklao hospital

khanisorn.meesri@gmail.com0643050789

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026